Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win
Tourmaline Bio’s lead candidate sparkled in a new mid-stage data drop, prepping the biotech to develop the former Pfizer asset further in a pair of cardiovascular indications.
Tourmaline Bio’s lead candidate sparkled in a new mid-stage data drop, prepping the biotech to develop the former Pfizer asset further in a pair of cardiovascular indications.
